{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:04:10Z","timestamp":1784822650804,"version":"3.55.0"},"reference-count":39,"publisher":"Akademiai Kiado Zrt.","issue":"23","license":[{"start":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T00:00:00Z","timestamp":1717891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"crossref","award":["\u00daNKP-23-3-I-PTE-1852"],"award-info":[{"award-number":["\u00daNKP-23-3-I-PTE-1852"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,6,9]]},"abstract":"A myeloma multiplex diagnosztik\u00e1ja \u00e9s kezel\u00e9se ter\u00e9n jelent\u0151s el\u0151rel\u00e9p\u00e9sek\n t\u00f6rt\u00e9ntek az elm\u00falt \u00e9vek sor\u00e1n. Az immunmodul\u00e1ns \u00e1gensek, a proteasz\u00f3mag\u00e1tl\u00f3k \u00e9s\n a nagy d\u00f3zis\u00fa melfal\u00e1nnal val\u00f3 kondicion\u00e1l\u00e1st k\u00f6vet\u0151 autol\u00f3g haemopoeticus\n \u0151ssejt-transzplant\u00e1ci\u00f3 bevezet\u00e9se lehet\u0151v\u00e9 tette a m\u00e9lyebb ter\u00e1pi\u00e1s v\u00e1lasz \u00e9s a\n hosszabb t\u00e1v\u00fa t\u00fal\u00e9l\u00e9s el\u00e9r\u00e9s\u00e9t. Ennek ellen\u00e9re a szakirodalom tov\u00e1bbra is a\n betegs\u00e9g gy\u00f3gy\u00edthatatlans\u00e1g\u00e1t hangs\u00falyozza, mivel a remisszi\u00f3k \u00e9s a relapsusok\n v\u00e1ltakoz\u00e1sa tov\u00e1bbra is meghat\u00e1rozza a k\u00f3rk\u00e9p lefoly\u00e1s\u00e1t. A myeloma multiplex\n eset\u00e9ben a definit\u00edv gy\u00f3gyul\u00e1shoz elengedhetetlen a gy\u00f3gyszer-rezisztencia\n lek\u00fczd\u00e9se \u00e9s a tart\u00f3s v\u00e1lasz biztos\u00edt\u00e1sa. Ennek el\u00e9r\u00e9s\u00e9hez \u00faj ter\u00e1pi\u00e1s\n strat\u00e9gi\u00e1k kidolgoz\u00e1s\u00e1ra \u00e9s \u00e9rz\u00e9kenyebb diagnosztikus eszk\u00f6zt\u00e1rra van sz\u00fcks\u00e9g.\n K\u00f6zlem\u00e9ny\u00fcnk c\u00e9lja a jelenleg alkalmazott kezel\u00e9si ir\u00e1nyelvek \u00e1ttekint\u00e9se\n mellett az \u00faj diagnosztikus elj\u00e1r\u00e1sok \u00e9s a klinikai vizsg\u00e1latokban szerepl\u0151\n ter\u00e1pi\u00e1s strat\u00e9gi\u00e1k \u00f6sszefoglal\u00e1sa, melyek jav\u00edthatj\u00e1k a betegek \u00e9letmin\u0151s\u00e9g\u00e9t\n \u00e9s t\u00fal\u00e9l\u00e9si es\u00e9lyeit. A modern diagnosztikus m\u00f3dszerek lehet\u0151v\u00e9 teszik a\n betegs\u00e9g korai felismer\u00e9s\u00e9t, a szem\u00e9lyre szabott, biol\u00f3giai alap\u00fa kezel\u00e9sek\n bevezet\u00e9s\u00e9t \u00e9s a v\u00e1laszadapt\u00e1lt ter\u00e1pia alkalmaz\u00e1s\u00e1t. Tov\u00e1bb\u00e1 az immunter\u00e1pi\u00e1s\n strat\u00e9gi\u00e1k kor\u00e1bbi kezel\u00e9si vonalakba val\u00f3 be\u00e9p\u00fcl\u00e9se a j\u00f6v\u0151ben megk\u00e9rd\u0151jelezheti\n a betegs\u00e9g gy\u00f3gy\u00edthatatlans\u00e1g\u00e1r\u00f3l kialak\u00edtott elk\u00e9pzel\u00e9seket. Orv Hetil. 2024;\n 165(23): 891\u2013899.<\/jats:p>","DOI":"10.1556\/650.2024.33036","type":"journal-article","created":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T11:26:41Z","timestamp":1717932401000},"page":"891-899","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":3,"title":["Az el\u00e9rhet\u0151 gy\u00f3gyul\u00e1s k\u00fcsz\u00f6b\u00e9n: innov\u00e1ci\u00f3k a myeloma multiplex kezel\u00e9s\u00e9ben"],"prefix":"10.1556","volume":"165","author":[{"given":"T\u00fcnde","family":"T\u00f3th","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, Klinikai K\u00f6zpont, I. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13., 7624 Magyarorsz\u00e1g"},{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Anat\u00f3miai Int\u00e9zet P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussain","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, Klinikai K\u00f6zpont, I. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13., 7624 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J\n Clin. 2019; 69: 7\u201334.","DOI":"10.3322\/caac.21551"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple\n myeloma. Nat Rev Cancer 2017; 17: 543\u2013556.","DOI":"10.1038\/nrc.2017.63"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Updated diagnostic criteria and staging system for\n multiple myeloma. Am Soc Clin Oncol Educ Book 2016; 35:\n e418\u2013e423.","DOI":"10.1200\/EDBK_159009"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Murray DL. Bringing mass spectrometry into the care of patients with\n multiple myeloma. Int J Hematol. 2022; 115: 790\u2013798.","DOI":"10.1007\/s12185-022-03364-2"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Hillengass J, Martin T, Puig N, et al. Disease monitoring in\n multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023; 23:\n 244\u2013248.","DOI":"10.1016\/j.clml.2023.01.005"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Claveau JS, Murray DL, Dispenzieri A, et al. Value of bone marrow\n examination in determining response to therapy in patients with multiple myeloma\n in the context of mass spectrometry-based M-protein assessment. Leukemia 2023;\n 37: 1\u20134.","DOI":"10.1038\/s41375-022-01779-8"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"T\u00f3th T, Alizadeh H, Polg\u00e1r B, et al. Diagnostic and prognostic value\n of PACAP in multiple myeloma. Int J Mol Sci. 2023; 24: 10801.","DOI":"10.3390\/ijms241310801"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Kor\u00f3zs D, Jen\u0151fi N, Szab\u00f3 BG, et al. \u201cWhen it rains, it pours\u201d \u2013\n de novo diagnosed multiple myeloma with invasive\n Streptococcus pneumoniae infection in severe COVID\u201319\n complicated with cytokine storm. [\u201eA baj nem j\u00e1r egyed\u00fcl\u201d \u2013 de\n novo diagnosztiz\u00e1lt myeloma multiplex invaz\u00edv Streptococcus\n pneumoniae fert\u0151z\u00e9ssel citokinviharral sz\u00f6v\u0151d\u00f6tt COVID\u201319-ben.] Orv\n Hetil. 2023; 164: 763\u2013769. [Hungarian]","DOI":"10.1556\/650.2023.32785"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Frenzel L, Decaux O, Macro M, et al. Venous thromboembolism\n prophylaxis and multiple myeloma patients in real-life: Results of a large\n survey and clinical guidance recommendations from the IFM group. Thromb Res.\n 2024; 233: 153\u2013164.","DOI":"10.1016\/j.thromres.2023.11.021"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic\n acid in bone disease treatment of newly diagnosed multiple myeloma: an\n international, double-blind, double-dummy, randomised, controlled, phase 3\n study. Lancet Oncol. 2018; 19: 370\u2013381.","DOI":"10.1016\/S1470-2045(18)30072-X"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Coluzzi F, Rolke R, Mercadante S. Pain management in patients with\n multiple myeloma: an update. Cancers (Basel) 2019; 11: 2037.","DOI":"10.3390\/cancers11122037"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Mateos MV, Nooka AK, Larson SM. Moving toward a cure for myeloma. Am\n Soc Clin Oncol Educ Book 2022; 42: 1\u201312.","DOI":"10.1200\/EDBK_349603"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Lonial S, Jacobus S, Fonseca R, et al. Randomized trial of\n lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol.\n 2020; 38: 1126\u20131137.","DOI":"10.1200\/JCO.19.01740"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Kumar SK, Abdallah AO, Badros AZ, et al. Aggressive smoldering\n curative approach evaluating novel therapies (ASCENT): a phase 2 trial of\n induction, consolidation and maintenance in subjects with high risk smoldering\n multiple myeloma (SMM): initial analysis of safety data. Blood 2020; 136(Suppl\n 1): 35\u201336.","DOI":"10.1182\/blood-2020-142584"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Mateos MV, Martinez Lopez J, Rodr\u00edguez-Otero P, et al. Curative\n strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib,\n lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT,\n consolidation with Krd and maintenance with Rd. Blood 2021; 138(Suppl 1):\n 1829.","DOI":"10.1182\/blood-2021-148423"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide\n and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380:\n 2104\u20132115.","DOI":"10.1056\/NEJMoa1817249"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Kazandjian D, Hill E, Dew A, et al. Carfilzomib, lenalidomide, and\n dexamethasone followed by lenalidomide maintenance for prevention of symptomatic\n multiple myeloma in patients with high-risk smoldering myeloma: a phase 2\n nonrandomized controlled trial. JAMA Oncol. 2021; 7: 1678\u20131685.","DOI":"10.1001\/jamaoncol.2021.3971"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO\n clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere\n 2021; 5: e528. Erratum: Hemasphere 2021; 5(4): e567. Erratum: Hemasphere 2021;\n 5(12): e659.","DOI":"10.1097\/HS9.0000000000000659"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version\n 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw.\n 2023; 21: 1281\u20131301.","DOI":"10.6004\/jnccn.2023.0061"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Goel U, Usmani S, Kumar S. Current approaches to management of newly\n diagnosed multiple myeloma. Am J Hematol. 2022; 97(Suppl 1):\n 3\u201325.","DOI":"10.1002\/ajh.26512"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Rafae A, van Rhee F, Al Hadidi S. Perspectives on the treatment of\n multiple myeloma. Oncologist 2024; 29: 200\u2013212.","DOI":"10.1093\/oncolo\/oyad306"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Kiss S, Gede N, So\u00f3s A, et al. Efficacy of first-line treatment\n options in transplant-ineligible multiple myeloma: a network meta-analysis. Crit\n Rev Oncol Hematol. 2021; 168: 103504.","DOI":"10.1016\/j.critrevonc.2021.103504"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Phase 3 randomized\n study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd)\n versus VRd alone in patients (Pts) with newly diagnosed multiple myeloma (NDMM)\n who are eligible for autologous stem cell transplantation (ASCT): primary\n results of the perseus trial. Blood 2023; 142(Suppl 2): LBA-1.","DOI":"10.1182\/blood-2023-191911"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Gay F, Roeloffzen W, Dimopoulos MA, et al. Results of the phase III\n randomized Iskia Trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs\n carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and\n post-transplant consolidation in newly diagnosed multiple myeloma patients.\n Presented at: 65th ASH Annual Meeting and Exposition, December 9\u201312, 2023, San\n Diego, CA. Blood 2023; 142(Suppl 1): 4.","DOI":"10.1182\/blood-2023-177546"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Kiss Sz, Gede N, Hegyi P, et al. Addition of daratumumab to multiple\n myeloma backbone regimens significantly improves clinical outcomes: a systematic\n review and meta-analysis of randomised controlled trials. Sci Rep. 2021; 11:\n 21916.","DOI":"10.1038\/s41598-021-01440-x"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Dunavin NC, Wei L, Elder P, et al. Early versus delayed autologous\n stem cell transplant in patients receiving novel therapies for multiple myeloma.\n Leuk Lymphoma 2013; 54: 1658\u20131664.","DOI":"10.3109\/10428194.2012.751528"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Fazio M, Del Fabro V, Parrinello NL, et al. Multiple myeloma in 2023\n ways: from trials to real life. Curr Oncol. 2023; 30:\n 9710\u20139733.","DOI":"10.3390\/curroncol30110705"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Du J, Fu W, Lu J, et al. Phase I open-label single-arm study of\n BCMA\/CD19 dual-targeting FasT CAR-T cells (GC012F) as first-line therapy for\n transplant-eligible newly diagnosed high-risk multiple myeloma. Blood 2022;\n 140(Suppl): 889\u2013890.","DOI":"10.1182\/blood-2022-162295"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"de Jong MM, Kellermayer Z, Papazian N, et al. The multiple myeloma\n microenvironment is defined by an inflammatory stromal cell landscape. Nat\n Immunol. 2021; 22: 769\u2013780.","DOI":"10.1038\/s41590-021-00931-3"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Bilgihan MT, Eryigit AN, Ciftciler R. Efficacy and safety of immune\n checkpoint inhibitors in hematologic malignancies. Clin Lymphoma Myeloma Leuk.\n 2024; 24: 23\u201331.","DOI":"10.1016\/j.clml.2023.09.002"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Saltarella I, Altamura C, Campanale C, et al. Anti-angiogenic\n activity of drugs in multiple myeloma. Cancers (Basel) 2023; 15:\n 1990.","DOI":"10.3390\/cancers15071990"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Bouchlarhem A, Es-Saad O, Haddar L, et al. Special case of a patient\n in the blast phase of chronic myeloid leukemia successfully treated with\n tocilizumab during critical SARS-CoV-2 infection. J Int Med Res. 2022; 50:\n 3000605221082875.","DOI":"10.1177\/03000605221082875"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Montefusco V, Gay F, Spada S, et al. Outcome of paraosseous\n extra-medullary disease in newly diagnosed multiple myeloma patients treated\n with new drugs. Haematologica 2020; 105: 193\u2013200.","DOI":"10.3324\/haematol.2019.219139"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Tsang RW, Campbell BA, Goda JS, et al. Radiation therapy for\n solitary plasmacytoma and multiple myeloma: guidelines from the International\n Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018; 101:\n 794\u2013808. Erratum: Int J Radiat Oncol Biol Phys. 2018; 102:\n 1602.","DOI":"10.1016\/j.ijrobp.2018.08.004"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Szita VR, Wiedemann \u00c1, Syoreni S, et al. Venetoclax-based salvage in\n multiple myeloma with (11;14) translocation after suboptimal response to\n first-line therapy. [Venetoclaxalap\u00fa ment\u0151kezel\u00e9s (11;14)-transzlok\u00e1ci\u00f3s myeloma\n multiplexben az els\u0151 vonalbeli kezel\u00e9sre adott nem megfelel\u0151 v\u00e1lasz eset\u00e9n.] Orv\n Hetil. 2023; 164: 894\u2013899. [Hungarian]","DOI":"10.1556\/650.2023.32790"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Deng H, Liu M, Yuan T, et al. Efficacy of humanized anti-BCMA CAR T\n cell therapy in relapsed\/refractory multiple myeloma patients with and without\n extramedullary disease. Front Immunol. 2021; 12: 720571.","DOI":"10.3389\/fimmu.2021.720571"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Li W, Liu M, Yuan T, et al. Efficacy and follow-up of humanized\n anti-BCMA CAR-T cell therapy in relapsed\/refractory multiple myeloma patients\n with extramedullary-extraosseous, extramedullary-bone related, and without\n extramedullary disease. Hematol Oncol. 2022; 40: 223\u2013232.","DOI":"10.1002\/hon.2958"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Zanwar S, Ho M, Lin Y, et al. Natural history, predictors of\n development of extramedullary disease, and treatment outcomes for patients with\n extramedullary multiple myeloma. Am J Hematol. 2023; 98:\n 1540\u20131549.","DOI":"10.1002\/ajh.27023"},{"key":"R39","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working\n Group consensus criteria for response and minimal residual disease assessment in\n multiple myeloma. Lancet Oncol. 2016; 17: e328\u2013e346."}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/23\/article-p891.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/23\/article-p891.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/23\/article-p891.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:15:15Z","timestamp":1784819715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/23\/article-p891.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,9]]},"references-count":39,"journal-issue":{"issue":"23"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.33036","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,9]]}}}